As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical experts are increasingly recognising obesity as a serious chronic disease.

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in the science behind obesity. Learn more about our ambitious R&D pipeline.

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future where we can help prevent and treat obesity – and even ultimately cure it.

Here you will find everything related to our obesity treatments, information on how to use your medication devices, as well as information about our clinical trials, and our treatment innovations. Explore our obesity page.

Jan 27, 2025 · Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the...

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.

Novo Nordisk® is committed to discovering, developing, and delivering resources and tools to help enhance weight-loss discussion and motivate healthy changes.

Feb 3, 2025 · Based on the results, Novo Nordisk is planning further clinical developments for the drug in adults with obesity and overweight. 1. REFERENCES 1. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. News release. Novo Nordisk. January 24, 2025.

Jan 28, 2025 · Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are planned. ... Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials. By Clara Rodriguez Fernandez . 28-Jan-2025 Last updated on 28-Jan-2025 at 14:25 GMT.

As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Adults and children are currently living with obesity globally. The global prevalence of obesity has more than tripled since 1975.